BOS Trademark

Trademark Overview

On Thursday, July 20, 2023, a trademark application was filed for BOS with the United States Patent and Trademark Office. The USPTO has given the BOS trademark a serial number of 98094182. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, April 21, 2025. This trademark is owned by Boston Oncology, LLC. The BOS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

pharmaceutical research and development; consultation in the field of pharmaceutical research and development
bos

General Information

Serial Number98094182
Word MarkBOS
Filing DateThursday, July 20, 2023
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, April 21, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicespharmaceutical research and development; consultation in the field of pharmaceutical research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, August 20, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBoston Oncology, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Monday, July 24, 2023NEW APPLICATION ENTERED
Sunday, August 20, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 7, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, August 30, 2023ASSIGNED TO EXAMINER
Thursday, September 7, 2023NON-FINAL ACTION WRITTEN
Thursday, September 7, 2023NON-FINAL ACTION E-MAILED
Thursday, September 7, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, August 20, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 7, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, December 7, 2023TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, March 6, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 20, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 20, 2024ASSIGNED TO LIE
Wednesday, October 2, 2024NON-FINAL ACTION E-MAILED
Wednesday, October 2, 2024NON-FINAL ACTION WRITTEN
Thursday, December 19, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, April 21, 2025ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, April 21, 2025ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Thursday, December 19, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, August 20, 2024PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, October 2, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED

Related Keywords

pharmaceutical development research field consultation